MORE►
nanotechnology
The Fort Worth oncology company tapped former Salarius Pharmaceuticals CEO David Arthur to lead its push toward commercialization, including a planned IND for a rare pediatric brain cancer program.
NanOlogy Names CEO as Its Tumor-Targeted Cancer Drugs Near Key Regulatory Milestones
by Sandra Engelland | Dec 30, 2025
The Fort Worth oncology company tapped former Salarius Pharmaceuticals CEO David Arthur to lead its push toward commercialization, including a planned IND for a rare pediatric brain cancer program.
by Sandra Engelland |
Nov 20, 2025
With more than two decades of experience in product development, strategic operations, and commercial execution across the biotechnology industry, Brent Sorrells will help drive OncoNano’s next phase of growth and operational excellence, the company said.
MORE►
by Quincy Preston and Sandra Engelland |
Feb 23, 2021
From ABIA to Zyvex, Dallas-Fort Worth companies are at the forefront of innovations in AI, 5G, quantum computing, genomics, and more.
MORE►
by Quincy Preston |
Oct 7, 2020
The Lewisville-based company's new fusion system is designed to compress and stabilize the sacroiliac joint. Its high-tech features make it the first of its kind specifically designed for SI joint solutions.
Other recent news includes a $10 million partnership with a Swiss medtech firm and a new division president.
Other recent news includes a $10 million partnership with a Swiss medtech firm and a new division president.
MORE►
[Photo by shutter_m via iStock]
IBM Offers 5 Predictions of Life-Changing Innovations
by Lance Murray | Jan 9, 2017
The predictions — nicknamed IBM 5 in 5 — were drawn from more than 3,000 researchers in 12 laboratories on six continents
MORE►
